- 'We Do Vaccines' and 'Know Our Vax' are new
educational efforts that provide information regarding
vaccines
- Programs explain Novavax' commitment to vaccine
development and innovation
GAITHERSBURG, Md., March 10, 2022 /CNW/ -- Novavax, Inc. (Nasdaq:
NVAX), a biotechnology company dedicated to developing and
commercializing next-generation vaccines for serious infectious
diseases, today announced the launch of its global unbranded 'We Do
Vaccines' and 'Know Our Vax' programs, educational efforts aimed to
help protect the health of people everywhere in the fight against
COVID-19 and other deadly infectious diseases, such as
influenza.
The 'We Do Vaccines' program helps provide educational
information about the common types of vaccines and how they work,
how vaccines are made and tested, and how Novavax' approach to
technology makes its vaccines different. The 'Know Our Vax' program
provides educational information about Novavax, its global
approach, and tried and true technology.
"Novavax' vaccines are built on a well-understood protein-based
platform used for other vaccines for decades, and we are committed
to fighting the current pandemic and aiding in overall global
public health," said John Trizzino,
Chief Commercial Officer and Chief Business Officer, Novavax.
"We're proud to do our part to ensure that all stakeholders have
awareness about their vaccine options through the launch of
educational programs such as these."
The programs intend to inspire people to learn more about how
vaccines have helped millions of lives and encourage those who have
not yet been vaccinated to consider a differentiated option. For
additional information, the consumer website is available at
www.wedovaccines.com and the healthcare provider website is
available at www.knowourvax.com.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a
biotechnology company that promotes improved health globally
through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The
company's proprietary recombinant technology platform harnesses the
power and speed of genetic engineering to efficiently produce
highly immunogenic nanoparticles designed to address urgent global
health needs. NVX-CoV2373, the company's COVID-19 vaccine, has
received conditional authorization from multiple regulatory
authorities globally, including the European Commission and the
World Health Organization. The vaccine is also under review by
multiple regulatory agencies worldwide. In addition to its COVID-19
vaccine, Novavax is also currently evaluating a COVID-seasonal
influenza combination vaccine in a Phase 1/2 clinical trial, which
combines NVX-CoV2373 and NanoFlu, its quadrivalent influenza
investigational vaccine candidate. These vaccine candidates
incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant
to enhance the immune response and stimulate high levels of
neutralizing antibodies.
For more information, visit www.novavax.com and
connect with us on
Twitter, LinkedIn, Instagram and Facebook.
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating
plans and prospects, its partnerships, the timing of clinical trial
results, the ongoing development of NVX-CoV2373, including a
COVID-seasonal influenza combination vaccine candidate with
NanoFlu, its quadrivalent influenza investigational vaccine
candidate, the scope, timing and outcome of future regulatory
filings and actions, the potential impact of Novavax and
NVX-CoV2373 in addressing global vaccine access and education,
controlling the pandemic, and protecting populations, and the
efficacy, safety, and intended utilization of NVX-CoV2373 are
forward-looking statements. Novavax cautions that these
forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, without limitation, challenges satisfying,
alone or together with partners, various safety, efficacy, and
product characterization requirements, including those related to
process qualification and assay validation, necessary to satisfy
applicable regulatory authorities; unanticipated challenges or
delays in conducting clinical trials; difficulty obtaining scarce
raw materials and supplies; resource constraints, including human
capital and manufacturing capacity, on the ability of Novavax to
pursue planned regulatory pathways; challenges meeting contractual
requirements under agreements with multiple commercial,
governmental, and other entities; and those other risk factors
identified in the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of Novavax' Annual Report on Form 10-K for the year ended
December 31, 2021, as filed with the
Securities and Exchange Commission (SEC). We caution investors not
to place considerable reliance on forward-looking statements
contained in this press release. You are encouraged to read our
filings with the SEC, available at www.sec.gov and www.novavax.com,
for a discussion of these and other risks and uncertainties. The
forward-looking statements in this press release speak only as of
the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com
Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey |
202-709-7521
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-announces-launch-of-global-vaccine-education-programs-301500118.html
SOURCE Novavax, Inc.